Jaffer Ajani

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation
    J A Ajani
    Br J Cancer 99:1195; author reply 1196. 2008
  2. pmc Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results
    Putao Cen
    Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center Houston, TX, USA
    Ther Clin Risk Manag 4:137-40. 2008
  3. pmc Review of docetaxel in the treatment of gastric cancer
    Eric D Tetzlaff
    Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Ther Clin Risk Manag 4:999-1007. 2008
  4. doi request reprint ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients
    J A Ajani
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA Electronic address
    Mol Oncol 8:142-9. 2014
  5. doi request reprint Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study
    J A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA Electronic address
    Eur J Cancer 49:3616-24. 2013
  6. pmc Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer
    J A Ajani
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX 77030, USA
    Ann Oncol 23:2638-42. 2012
  7. pmc Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data Base
    Kaye M Reid-Lombardo
    Department of Surgery, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    J Gastrointest Surg 11:410-9; discussion 419-20. 2007
  8. pmc Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer
    Xiaoxiang Guan
    Department of Epidemiology, The University of Texas M, d, Anderson Cancer Center, Houston, Texas 77030, USA
    J Exp Clin Cancer Res 28:94. 2009
  9. pmc AGUIA: autonomous graphical user interface assembly for clinical trials semantic data services
    Miria C Correa
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    BMC Med Inform Decis Mak 10:65. 2010
  10. pmc The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer
    Xiaoxiang Guan
    Department of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    BMC Gastroenterol 9:77. 2009

Detail Information

Publications160 found, 100 shown here

  1. pmc Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation
    J A Ajani
    Br J Cancer 99:1195; author reply 1196. 2008
  2. pmc Contribution of capecitabine for therapy of patients with gastroesophageal cancer: an update of recent phase III results
    Putao Cen
    Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center Houston, TX, USA
    Ther Clin Risk Manag 4:137-40. 2008
    ....
  3. pmc Review of docetaxel in the treatment of gastric cancer
    Eric D Tetzlaff
    Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Ther Clin Risk Manag 4:999-1007. 2008
    ..In addition, the current investigations of docetaxel for the treatment of potentially curable gastric cancer will be discussed...
  4. doi request reprint ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients
    J A Ajani
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston 77030, USA Electronic address
    Mol Oncol 8:142-9. 2014
    ..We hypothesized that aldehyde dehydrogenase-1 (ALDH-1) could be associated with response...
  5. doi request reprint Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study
    J A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA Electronic address
    Eur J Cancer 49:3616-24. 2013
    ..S-1, a novel oral fluoropyrimidine, was specifically designed to overcome the limitations of intravenous fluoropyrimidine therapies...
  6. pmc Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer
    J A Ajani
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX 77030, USA
    Ann Oncol 23:2638-42. 2012
    ..We hypothesized that a model based on clinical parameters could predict pathCR with a high (≥60%) probability...
  7. pmc Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data Base
    Kaye M Reid-Lombardo
    Department of Surgery, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
    J Gastrointest Surg 11:410-9; discussion 419-20. 2007
    ..9%) (p<0.01). These data support previous publications demonstrating that patients with diseases requiring specialized treatment have lower operative mortality when treated at high-volume centers...
  8. pmc Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer
    Xiaoxiang Guan
    Department of Epidemiology, The University of Texas M, d, Anderson Cancer Center, Houston, Texas 77030, USA
    J Exp Clin Cancer Res 28:94. 2009
    ..Given that these genes are involved in tumor growth and progression including angiogenesis, dissemination, and invasiveness, we hypothesized that these polymorphisms would be associated with survival in patients with gastric cancer...
  9. pmc AGUIA: autonomous graphical user interface assembly for clinical trials semantic data services
    Miria C Correa
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    BMC Med Inform Decis Mak 10:65. 2010
    ..AGUIA uses a semantic web formalism, resource description framework (RDF), and a bottom-up design of knowledge bases that employ the S3DB tool as the starting point for the client's interface assembly...
  10. pmc The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer
    Xiaoxiang Guan
    Department of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    BMC Gastroenterol 9:77. 2009
    ..In this study, we investigated the association between potentially functional SNPs of these two genes and risk of gastric cancer in a US population...
  11. pmc Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge!
    Jaffer A Ajani
    Ann Surg Oncol 14:3290-2. 2007
  12. ncbi request reprint Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:3210-6. 2007
    ..Using validated instruments, we prospectively assessed QOL (even after completion of protocol treatment) as one of the secondary end points of the V325 phase III trial...
  13. ncbi request reprint Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome
    J A Ajani
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 23:1237-44. 2005
    ....
  14. ncbi request reprint Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:3205-9. 2007
    ..However, a prospective evaluation of clinical benefit in AGGEC patients has never before been reported in a phase III setting...
  15. doi request reprint Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas 77030, USA
    JAMA 299:1914-21. 2008
    ..Chemoradiation as definitive therapy is the preferred primary therapy for patients with anal canal carcinoma; however, the 5-year disease-free survival rate from concurrent fluorouracil/mitomycin and radiation is only approximately 65%...
  16. doi request reprint Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:945-55. 2008
    ....
  17. ncbi request reprint Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma
    Julie G Izzo
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Mol Cancer Ther 5:2844-50. 2006
    ..We hypothesized that activated NF-kappaB would define clinical biology irrespective of the type of chemotherapy or sequence administered...
  18. ncbi request reprint Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:663-7. 2006
    ..We conducted a phase II multi-institutional trial, in the West, in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma to evaluate activity and safety of this combination...
  19. ncbi request reprint An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1908-16. 2006
    ..Immunogen G17DT elicits a specific and high-affinity AGA. The authors evaluated G17DT vaccination given with cisplatin plus 5-fluorouracil for the treatment gastric adenocarcinoma...
  20. ncbi request reprint A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane
    J A Ajani
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas, 77030, USA
    Invest New Drugs 24:441-6. 2006
    ..With the primary endpoint of assessing ixabepilone's response rate against metastatic gastric cancer previously treated with a taxane, we performed a multi-center phase II trial...
  21. ncbi request reprint Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:6957-65. 2005
    ..S-1 with cisplatin is considered highly active in Japanese gastric cancer patients. Therefore, we initiated a phase I pharmacokinetic study of this combination in our gastric cancer patients...
  22. ncbi request reprint A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer
    Jaffer A Ajani
    M D Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Box 426, Houston, TX, 77030, USA
    Invest New Drugs 23:479-84. 2005
    ....
  23. ncbi request reprint Molecular mechanisms in cancer: what should clinicians know?
    Jaffer Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Semin Oncol 32:2-4. 2005
    ..In this way, clinicians might recommend combinations of molecularly targeted agents and other therapies on the basis of an individual patient's proteomic profile...
  24. ncbi request reprint Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers
    Jaffer Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer 107:221-31. 2006
    ....
  25. ncbi request reprint Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel
    Jaffer A Ajani
    Department of GI Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, TX 77030, USA
    Expert Opin Pharmacother 7:1627-31. 2006
    ..Future developments will lead to the incorporation of docetaxel in regimens with improved safety profile...
  26. ncbi request reprint Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Box 426, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:5660-7. 2005
    ..We compared the overall response rate (ORR) and safety of docetaxel plus cisplatin (DC) with DC plus fluorouracil (DCF) to select either DC or DCF as the experimental treatment in the ensuing phase III part of trial V-325...
  27. ncbi request reprint Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 24:3953-8. 2006
    ..We hypothesized that, in a cooperative group setting, preoperative chemoradiotherapy would induce a 20% pathologic complete response (pathCR) rate. Combined-modality therapy quality, survival, and safety were secondary end points...
  28. ncbi request reprint Evolving chemotherapy for advanced gastric cancer
    Jaffer A Ajani
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, Texas 77030, USA
    Oncologist 10:49-58. 2005
    ..Recently reported phase III results with these agents now demonstrate positive developments in the treatment options for patients with advanced gastric cancer...
  29. ncbi request reprint Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma
    J A Ajani
    Department of Gastrointestinal Medical Oncology, Stop 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 22:2774-80. 2004
    ..A multi-institutional study of preoperative chemoradiotherapy was done to assess the R0 resection rate, pathologic complete response (pathCR) rate, safety, and survival in patients with resectable gastric carcinoma...
  30. pmc US intergroup anal carcinoma trial: tumor diameter predicts for colostomy
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, TX 77030 4009, USA
    J Clin Oncol 27:1116-21. 2009
    ..Established prognostic variables for patients with anal carcinoma include tumor diameter, clinical nodal status, and sex, but pretreatment variables that would predict the likelihood of colostomy are unknown...
  31. doi request reprint Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 116:1656-63. 2010
    ..It was hypothesized that chemoradiotherapy with fluoropyrimidine, taxane, and camptothecin would have preserved or improved efficacy with no compromise in safety...
  32. ncbi request reprint Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma
    J A Ajani
    Department of GI Oncology, Box 78, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4095, USA
    Oncology (Williston Park) 15:52-4. 2001
    ..The combination of irinotecan and cisplatin is active against gastric or gastroesophageal adenocarcinoma and should undergo further study. The addition of other active drugs or radiation therapy to this regimen would be of interest...
  33. ncbi request reprint A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction
    J A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 92:279-86. 2001
    ..After chemoradiotherapy, patients underwent surgery. The feasibility of this approach, curative resection rates, patient survival, and patterns of failure were assessed...
  34. doi request reprint Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, TX 77030, USA
    J Clin Oncol 28:1547-53. 2010
    ..Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious and safer treatments than established today. S-1, a contemporary oral fluoropyrimidine, can provide that advantage...
  35. pmc Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11)
    Jaffer A Ajani
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4007-13. 2010
    ..A prognostic factor analysis for anal cancer from a prospective database has been published from only 1 study (N = 110). To confirm and uncover new prognostic factors, we analyzed the prospective database of intergroup RTOG 98-11...
  36. ncbi request reprint Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 16:16-8. 2002
    ..Modifications in doses and schedule are warranted to increase the tolerability of the regimen. Phase III trials are necessary to establish the clinical utility of irinotecan/cisplatin in these patient populations...
  37. ncbi request reprint Docetaxel for gastric and esophageal carcinomas
    Jaffer A Ajani
    Department of Gastrointestinal Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030 4009, USA
    Oncology (Williston Park) 16:89-96. 2002
    ....
  38. ncbi request reprint [Is neoadjuvant therapy for locally advanced stomach carcinoma standard?]
    J A Ajani
    Department of GI Oncology, Box 426, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Chirurg 73:312-5. 2002
    ....
  39. ncbi request reprint Recent developments in oral chemotherapy options for gastric carcinoma
    J A Ajani
    Department of Gastrointestinal Medical Oncology and Digestive Diseases, University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Drugs 58:85-90. 1999
    ..In conclusion, future clinical research is likely to focus on the development of convenient outpatient regimens with efficacy equal to that of intravenous regimens...
  40. ncbi request reprint CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:641-6. 2002
    ..This Phase II study assessed the response rate and toxicity profile of the combination CPT-11 and cisplatin administered weekly to patients with untreated, advanced adenocarcinoma of the stomach or the gastroesophageal junction...
  41. ncbi request reprint Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction
    Jaffer A Ajani
    Department of Gastrointestinal Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 17:10-2. 2003
  42. ncbi request reprint Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma
    J A Ajani
    Department of Gastrointestinal Oncology and Digestive Diseases, U T M D Anderson Cancer Center, Houston, TX 77030, USA
    Invest New Drugs 16:175-7. 1998
    ..We studied a 120-hour infusion schedule of Taxol in patients with metastatic measurable colorectal carcinoma who had had one prior 5-FU-based chemotherapy...
  43. ncbi request reprint Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma
    J A Ajani
    Departments of Gastrointestinal Medical Oncology and Digestive Diseases and Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    J Clin Oncol 17:2403-11. 1999
    ....
  44. ncbi request reprint Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:2347-54. 2004
    ..Patients with localized esophageal carcinoma often develop locoregional and distant disease recurrence. The current study investigated the outcome of a new chemotherapy combination as induction therapy before chemoradiotherapy...
  45. doi request reprint Future developments in esophageal cancer research
    Jaffer A Ajani
    Department of GI Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gastroenterol Clin North Am 38:183-8, x. 2009
    ..The progress that has been made against esophageal carcinoma is limited. Many relevant issues remain. Herein the author discusses his outlook for the treatment of this disease, which has a steadily rising incidence...
  46. doi request reprint Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Dig Dis Sci 55:1098-105. 2010
    ..Upon further expansion and validation, these results may provide a biomarker-based understanding of heterogeneous clinical biology of patients with anal carcinoma...
  47. pmc Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4551-6. 2008
    ..The primary end point was to assess whether any approach would achieve a >or= 77.5% 1-year survival rate, surpassing the historical 66% rate from the Radiation Therapy Oncology Group (RTOG) protocol 9405...
  48. ncbi request reprint Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 17:20-2. 2003
    ..Our preliminary data suggest that the proportion of patients with significant pathologic response can be increased by using the three-step strategy...
  49. ncbi request reprint Docetaxel-related side effects and their management
    Jackie Baker
    University of Texas MD Anderson Cancer Center, Gastrointestinal Medical Oncology, Faculty Center, Houston, TX 77030, USA
    Eur J Oncol Nurs 13:49-59. 2009
    ..It is, therefore, important to share and build on experiences, through research and discussion, to maximise the healthcare professional's ability to offer the best standard of care to patients...
  50. pmc Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer
    Matthew McCurdy
    Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 76:816-23. 2010
    ..The primary aim of this study was to assess pulmonary radiation toxicity quantitatively in patients who received thoracic radiotherapy combined with induction and/or concurrent chemotherapy with or without taxanes for esophageal cancer...
  51. ncbi request reprint Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus
    Pooja R Rohatgi
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1349-55. 2005
    ..The current study was conducted to test the hypothesis that patterns of failure are correlated with the degree of residual carcinoma after preoperative chemoradiotherapy (CRT) in patients with esophageal carcinoma...
  52. ncbi request reprint Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response
    Jennifer Sims-Mourtada
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:6565-72. 2006
    ..However, the relationship between Hh signaling and therapeutic response is unknown...
  53. ncbi request reprint Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction
    Kazumasa Fujitani
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 444, P.O. Box 301402, Houston, TX 77230-1402, USA
    Ann Surg Oncol 14:1305-11. 2007
    ....
  54. doi request reprint Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus
    Heta Javeri
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1302-8. 2008
    ..Whether the type of therapy influences the outcomes remains largely unanswered. It is hypothesized that induction chemotherapy (IC) or the type of cytotoxics used would not influence patient outcomes...
  55. ncbi request reprint Treatment issues in pediatric gastric adenocarcinoma
    Matthew T Harting
    Department of Pediatric Surgical Oncology, M D Anderson Cancer Center, Houston, TX, USA
    J Pediatr Surg 39:e8-10. 2004
    ..The authors report a case of an 8-year-old girl with gastric adenocarcinoma. The case will be followed by a brief discussion of the presentation, current management guidelines, and prognosis of this rare pediatric entity...
  56. ncbi request reprint Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux
    Banke Agarwal
    Department of Gastrointestinal Medicine and Nutrition, M D Anderson Cancer Center, Houston, Texas, USA
    Ann Thorac Surg 79:1716-23. 2005
    ..In this study, we investigated potential differences in clinical outcomes in esophageal adenocarcinoma patients based on the presence of identifiable Barrett's mucosa and/or history of symptomatic GERD...
  57. ncbi request reprint Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer
    James C Yao
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:4109-17. 2004
    ..Given the importance of Sp1 in the expression of VEGF, our data suggest that dysregulated Sp1 expression and activation play important roles in VEGF overexpression and, thus, gastric cancer development and progression...
  58. doi request reprint Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX 77030, USA
    Cancer 116:1446-53. 2010
    ..The objective of the current study was to evaluate the efficacy and tolerability of a weekly formulation of DCF...
  59. ncbi request reprint Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma
    Julie G Izzo
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 24:748-54. 2006
    ..Nuclear factor kappaB (NF-kappaB), a transcriptional factor, is constitutively activated or treatment induced in esophageal cancer and may influence treatment outcomes...
  60. ncbi request reprint Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection
    Banke Agarwal
    Department of GI Medicine and Nutrition, Medical Oncology and Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, Texas, USA
    Am J Gastroenterol 99:1258-66. 2004
    ..Based on these data, we reevaluated the role of EUS in identifying patients who maximally benefit from surgical esophageal resection after preoperative chemoXRT...
  61. ncbi request reprint Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer
    Shu Lian Wang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    World J Gastroenterol 12:5501-8. 2006
    ..To evaluate the dosimetry, efficacy and toxicity of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy for patients with locally advanced cervical and upper thoracic esophageal cancer...
  62. ncbi request reprint A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer
    Yixing Jiang
    Department of Gastrointestinal Medical Oncology, The University of Texas, MD, Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Exp Metastasis 21:755-64. 2004
    ..Therefore, dysregulated expression of IGF-IR and/or Sp1 may contribute to the growth and metastasis of gastric cancer and potentially can be a target of therapeutic intervention...
  63. ncbi request reprint Rapid development of S-1 in the west for therapy of advanced gastric carcinoma
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Gan To Kagaku Ryoho 33:117-20. 2006
    ..Phase I/II studies of the combination of S-1 plus cisplatin have been completed and a global phase III study, accruing rapidly, is comparing S-1 plus cisplatin to 5-fluorouracil plus cisplatin (a reference regimen)...
  64. ncbi request reprint Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma
    David Hong
    Department of GI Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1620-6. 2005
    ..The authors tested the hypothesis that, in this setting, the number of PET abnormalities (NPA) would correlate with OS and DFS...
  65. ncbi request reprint Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome
    Kim L Wang
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 109:658-67. 2007
    ..It is not known whether EGFR plays a similar role in esophageal and EGJ adenocarcinomas...
  66. ncbi request reprint The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation
    Yan Gu
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1017-25. 2006
    ..However, the prognostic significance of the number of LNs with residual metastasis remains unclear...
  67. ncbi request reprint Loss of Krüppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression
    Masashi Kanai
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:6395-402. 2006
    ..We have recently reported that Sp1 overexpression is directly correlated with the angiogenic potential of and poor prognosis for human gastric cancer. However, the underlying mechanisms that result in Sp1 overexpression remain unclear...
  68. ncbi request reprint Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index
    Arthur Hung
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:1195-202. 2003
    ..In the current study, the authors evaluated their experience in treating anal carcinoma with combined modality therapy using cisplatin and 5-FU...
  69. ncbi request reprint Gastric cancer: advances in adjuvant and adjunct therapy
    Katsuhiko Higuchi
    Department of Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Box 426, Houston, TX 77030, USA
    Curr Treat Options Oncol 4:413-9. 2003
    ..In our opinion, all of the patients in the West who have had a curatively resected node-positive gastric carcinoma (R0 resection) should be offered an option of receiving postoperative chemoradiotherapy...
  70. doi request reprint The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma
    Santosh B Murthy
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 78:316-22. 2010
    ..We hypothesized that the standardized uptake value (SUV) of positron emission tomography (PET) after chemoradiation would define the clinical outcome in patients...
  71. ncbi request reprint Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation
    Lucian R Chirieac
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:1347-55. 2005
    ....
  72. pmc Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma
    Chia Jui Yen
    Department of Molecular and Cellular Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 68:2632-40. 2008
    ..In addition, Bay 11-7082 and rapamycin may potentially be chemopreventive drugs against Barrett's esophagus-associated EAC...
  73. doi request reprint Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis
    Nirav Thosani
    Department of Gastroenterology, Hepatology and Nutrition, The University of Texas Medical School, Houston, Texas 77030, USA
    Gastrointest Endosc 75:242-53. 2012
    ..EC limited to the mucosa (T1a) can be treated effectively with minimally invasive endoscopic therapy, whereas submucosal (T1b) EC carries relatively high risk of lymph node metastasis and requires surgical resection...
  74. doi request reprint Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation
    Heta Javeri
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:624-30. 2009
    ..The authors evaluated initial standardized unit value (iSUV) of 18F-fluoro-2-deoxy-D-glucose positron emission tomography and its association with overall survival and the degree of pathologic response after surgery...
  75. ncbi request reprint A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
    Jaffer A Ajani
    Department of GI Medical Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Invest New Drugs 24:353-7. 2006
    ..Bryostatin-1 also increases cytotoxicity of paclitaxel in a sequential fashion. We studied sequential paclitaxel and bryostatin-1 in patients with untreated, advanced gastric adenocarcinoma...
  76. ncbi request reprint Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction
    Kazumasa Fujitani
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Ann Surg Oncol 14:2010-7. 2007
    ....
  77. ncbi request reprint Clinical benefit of palliative radiation therapy in advanced gastric cancer
    Michelle M Kim
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Acta Oncol 47:421-7. 2008
    ..Local progression of advanced gastric cancer often manifests as bleeding, dysphagia/obstruction, or pain. We evaluated the magnitude and durability of palliation with radiotherapy (RT)...
  78. ncbi request reprint Medical treatment for advanced gastroesophageal adenocarcinoma
    Putao Cen
    Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Gastroenterol 23:631-5. 2007
    ..Advanced gastroesophageal cancer is an incurable condition and more research is desirable. Considerable new and important information, however, has become available...
  79. ncbi request reprint Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers
    Madan G Luthra
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77054, USA
    Clin Cancer Res 13:912-9. 2007
    ..In the current study, we did an in-depth investigation of the expression of 1q21-1q25 region genes to uncover the role of the EDC and its flanking genes in CTXRT response...
  80. pmc Treatment outcomes of resected esophageal cancer
    Wayne Hofstetter
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg 236:376-84; discussion 384-5. 2002
    ..To assess the evolution of treatment and outcome for resected esophageal cancer at a single institution...
  81. ncbi request reprint Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus
    Pooja R Rohatgi
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Int J Gastrointest Cancer 36:69-76. 2005
    ..To analyze the differences in clinical stage, pathologic response to chemoradiotherapy, patterns of failure, and overall survival (OS) between patients with squamous cell carcinoma (SCC) and adenocarcinoma (ACA) of the esophagus...
  82. ncbi request reprint Effects of sex and racial/ethnic group on the pattern of gastric cancer localization
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gastric Cancer 5:208-12. 2002
    ..In Western countries, the overall incidence of gastric cancer is declining, while the incidence of proximal gastric cancer is rising. We evaluated the effect of sex, racial/ethnic group, and age on the localization of gastric cancer...
  83. doi request reprint Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins
    John A Harvin
    Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Cardiovasc Surg 143:412-20. 2012
    ..We aimed to determine the frequency and significance of a close (<1 mm) or involved CRM in patients undergoing esophagectomy after CRT...
  84. ncbi request reprint Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer
    Liwei Wang
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:6371-80. 2003
    ..Given the importance of Sp1 in the expression of multiple molecules key to tumor cell survival, growth, and angiogenesis, its disregulated expression and activation may play important roles in gastric cancer development and progression...
  85. ncbi request reprint Docetaxel-related side effects and their management
    Jackie Baker
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Eur J Oncol Nurs 12:253-68. 2008
    ..It is therefore important to share and build on experiences, through research and discussion, to maximise the healthcare professional's ability to offer the best standard of care to patients...
  86. pmc Prognostic significance of differentially expressed miRNAs in esophageal cancer
    Yuxin Hu
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX77030, USA
    Int J Cancer 128:132-43. 2011
    ..Our data indicate that further evaluation of miR-30e and miR-16-2 as prognostic biomarkers is warranted in patients with esophageal adenocarcinoma. In addition, the role of miR-34a in esophageal cancer also warrants further study...
  87. doi request reprint Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy
    Valerie K Reed
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:741-7. 2008
    ..To retrospectively determine the incidence and patterns (in-field, marginal, or out-of-field) of locoregional gastric cancer recurrence in patients who received preoperative chemoradiotherapy and to determine the outcome in these patients...
  88. ncbi request reprint Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging
    Jeremy J Erasmus
    Department of Diagnostic Imaging, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 1:478-86. 2006
    ..We evaluated the use of integrated computed tomography (CT)-PET among patients with esophageal cancer being considered for resection after CRT...
  89. doi request reprint Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma
    Putao Cen
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:1020-7. 2008
    ..The authors hypothesized that LVI status would subclassify T1b cancers and facilitate new therapeutic strategies...
  90. ncbi request reprint Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome
    Tsung Teh Wu
    Department of Pathology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Surg Pathol 31:58-64. 2007
    ..The extent of residual carcinoma is a reliable and reproducible predictor of survival; this grading system may allow a novel and early means of comparing outcomes after different neoadjuvant treatment regimens...
  91. ncbi request reprint Preoperative and adjuvant therapies for upper gastrointestinal cancers
    Gauri Varadhachary
    MD Anderson Cancer Center, GI Medical Oncology Department, University of Texas, 1515 Holcombe Boulevard, Mailbox 426, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 5:719-25. 2005
    ..The role of molecular profiling is evolving and will help us differentiate the responders from the nonresponders...
  92. ncbi request reprint Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma
    Lucian R Chirieac
    Department of Pathology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:2229-36. 2005
    ..Some adenocarcinomas have mixed patterns, including signet-ring cell and mucinous histology, but the clinical significance of these subtypes is unknown...
  93. ncbi request reprint Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin
    Eric D Tetzlaff
    Department of Gastrointestinal Medical Oncology, Box 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gastric Cancer 9:140-3. 2006
    ..This patient exemplifies the strategy of maintenance therapy with S-1 alone and shows a prolonged and excellent response to S-1 and cisplatin...
  94. ncbi request reprint Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma
    Lixia Liu
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 29:1079-85. 2005
    ....
  95. doi request reprint Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery
    Michelle M Kim
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:167-72. 2008
    ....
  96. pmc The crosstalk of mTOR/S6K1 and Hedgehog pathways
    Yan Wang
    Department of Molecular and Cellular Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 21:374-87. 2012
    ..Together, our results established a crosstalk between the mTOR/S6K1 and HH pathways, which provides a mechanism for SMO-independent Gli1 activation and also a rationale for combination therapy for EAC...
  97. ncbi request reprint Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients
    Bouthaina S Dabaja
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:518-26. 2004
    ..Primary adenocarcinoma of the small bowel is a rare neoplasm, and to the authors' knowledge, few studies to date have addressed the topic...
  98. ncbi request reprint Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung
    Thomas Guerrero
    Division of Radiation Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:1030-5. 2007
    ..To quantify the relationship between the local radiation dose received and the posttreatment positron emission tomography/computed tomography (PET/CT) [(18)F]2-fluoro-2-deoxyglucose (FDG) uptake in the lung...
  99. pmc MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma
    Hushan Yang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:5744-52. 2009
    ..Although microRNA (miRNA) expression signatures have been associated with the etiology and prognosis of several types of cancers, their roles in the development of esophageal adenocarcinoma have not been extensively evaluated...
  100. ncbi request reprint Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma
    Putao Cen
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:503-10. 2008
    ..It was hypothesized that endoscopic ultrasonography (EUS) in concert with detailed histopathologic evaluation would identify low-risk cancers for an appropriate but organ-preserving strategy...
  101. doi request reprint Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy
    Fadi Braiteh
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:4450-8. 2009
    ..For this study, the authors explored their institution's large surgical experience to examine the impact of age on long-term patient survival and surgical complications...

Research Grants2

  1. Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
    Jaffer A Ajani; Fiscal Year: 2010
    ..Our goal is to pave the way for a strategy in the future that will allow administration of effective therapy, improve safety, and preserve the esophagus in some patients. ..